Intralymphatic immunotherapy with tyrosine-adsorbed allergens: a double-blind, placebo-controlled trial
| Autor: | Sang Pyo Lee, Joo Hyun Jung, Chul Hwan Park, Dae Woo Kim, Il Gyu Kang, Sae Hoon Kim, So Hyun Park, Yoo Seob Shin, Sang Min Lee, Min Suk Yang, Myoung Seok Lee, Hye Jung Park, Eun-Suk Cho, Seung Joon Choi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Allergen immunotherapy Visual analogue scale medicine.medical_treatment Placebo-controlled study Basophil medicine.disease_cause Allergic rhinitis Diseases of the respiratory system 03 medical and health sciences Dogs 0302 clinical medicine Allergen Double-Blind Method Internal medicine medicine Animals Humans Antigens Dermatophagoides 030223 otorhinolaryngology Adverse effect Saline Retrospective Studies RC705-779 business.industry Research Injections Intralymphatic Immunotherapy Rhinitis Allergic Treatment Outcome medicine.anatomical_structure 030228 respiratory system Desensitization Immunologic Treatment efficacy Adverse events Cats Quality of Life Tyrosine Female business Intralymphatic injection Follow-Up Studies |
| Zdroj: | Respiratory Research, Vol 22, Iss 1, Pp 1-13 (2021) Respiratory Research |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-021-01766-0 |
| Popis: | Background Most previous studies used aluminum hydroxide-absorbed allergen extracts in evaluating the potential therapeutic roles of intralymphatic allergen-specific immunotherapy (ILAIT). In this study, we evaluated the therapeutic efficacy and safety of ILAIT with L-tyrosine-adsorbed allergen extracts of Dermatophagoides farinae, D. pteronyssinus, cat, dog, or mixtures thereof, in patients with allergic rhinitis induced by these allergens. Methods In this randomized, double-blind, placebo-controlled trial, study subjects received three intralymphatic injections of L-tyrosine-adsorbed allergen extracts (active group) or saline (placebo group) at 4-week intervals. Results Although ILAIT reduced daily medication use and skin reactivity to HDM and cat allergens at 4 months after treatment, overall symptom score on a visual analog scale (VAS), sinonasal outcome test-20 (SNOT-20), rhinoconjunctivitis quality of life questionnaire (RQLQ), daily symptom score (dSS), daily medication score (dMS), daily symptom medication score (dSMS), nasal reactivity to HDM allergen, and basophil activity to HDM, cat, and dog allergens at 4 months and 1 year after treatment were similar between the treatment and control groups. Intralymphatic injection was more painful than a venous puncture, and pain at the injection site was the most frequent local adverse event (12.8%); dyspnea and wheezing were the most common systemic adverse events (5.3%). Conclusions ILAIT with L-tyrosine-adsorbed allergen extracts does not exhibit profound therapeutic efficacy in allergic rhinitis and can provoke moderate-to-severe systemic reactions and cause pain at the injection site. Trial registration: clinicaltrials.gov: NCT02665754; date of registration: 28 January 2016 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink